Jennifer Bragg

6/12/2023  /  Drug Pricing , False Claims Act (FCA) , Fraud , Healthcare , Pharmaceutical Industry , Pharmacies , Prescription Drugs , Reasonable Interpretations , Safeco , Scienter , SCOTUS , US ex rel Thomas Proctor v Safeway Inc , US ex rel Tracy Schutte et al v SuperValu Inc et al

8/8/2022  /  Affordable Care Act , Clean Energy , Climate Change , Drug Pricing , Energy Sector , Energy Tax Incentives , Internal Revenue Code (IRC) , Oil & Gas , Renewable Energy

1/30/2020  /  Acquisitions , Administrative Procedure Act , Anti-Discrimination Policies , Anti-Harassment Policies , Anti-Kickback Statute , Antitrust Investigations , Appeals , Arbitration Awards , Attorney General , Backstop Agreements , BEPS , BitLicense , Blockchain , Board of Directors , Bonds , Capital Markets , CFIUS , CFTC , Chapter 11 , Claim Preclusion , Class Action , Commercial Bankruptcy , Common Stock , Congressional Investigations & Hearings , Congressional Subpoenas , Consumer Financial Protection Bureau (CFPB) , Cooperation Agreement , Copyright , Corporate Governance , Corporate Restructuring , Corporate Social Responsibility , Corporate Taxes , Corwin Doctrine , Covenant Lite Deals , Creditors , Cross-Border Transactions , DACA , DE Supreme Court , Debt Financing , Debtors , Department of Justice (DOJ) , Dischargeable Debts , Disgorgement , Disparate Impact , Dodd-Frank , Down Rounds , Drug Pricing , EBITDA , Employee Retirement Income Security Act (ERISA) , Employer Liability Issues , Employment Discrimination , Enforcement Actions , Enforcement of Foreign Judgments , Enterprise Act 2002 , Environmental Social & Governance (ESG) , EU , Fair Housing Act (FHA) , Federal Trade Commission (FTC) , FinTech , FIRRMA , Foreign Acquisitions , Foreign Investment , Foreign Issuers , FRCP 23 , General Data Protection Regulation (GDPR) , General Elections , GILTI tax , High-Yield Markets , Hong Kong , Hong Kong Stock Exchange , Individual Accountability , Initial Public Offering (IPO) , Intellectual Property Litigation , Intercreditor Agreements , International Arbitration , International Litigation , IRS , Issue Preclusion , Japan , Joint Venture , Legislative Agendas , Life Sciences , Listing Rules , Litigation Strategies , Make-Whole Premium , Mergers , MFW , Multinationals , National Security , PCAOB , Pharmaceutical Industry , Political Parties , Preferred Shares , Private Offerings , Privately Held Corporations , Proxy Advisory Firms , Publicly-Traded Companies , Refinancing , Regulatory Agenda , Reporting Requirements , SCOTUS , Securities and Exchange Commission (SEC) , Securities Litigation , Separation of Powers , Shareholder Activism , Shareholder Proposals , Shareholders , Split of Authority , State Labor Laws , Stock Drop Litigation , Tax Cuts and Jobs Act , Tax Litigation , Technology Sector , Third-Party Release Agrements , Transparency , UK , UK Brexit , Valuation , White Collar Crimes

1/24/2020  /  Anti-Kickback Statute , Data Privacy , Department of Health and Human Services (HHS) , Department of Justice (DOJ) , Drug Pricing , Enforcement Actions , False Claims Act (FCA) , Food and Drug Administration (FDA) , Fraud , Fraud and Abuse , Health Care Providers , Health Insurance Portability and Accountability Act (HIPAA) , Healthcare Costs , Imports , Innovation , Legislative Agendas , Life Sciences , Medical Devices , Medicare Part D , Pharmaceutical Industry , PHI , Prescription Drugs , Proposed Legislation , Settlement Agreements , State Legislatures , Trump Administration

12/2/2019  /  Anti-Kickback Statute , Big Data , CDRH , Charitable Organizations , Co-payments , Data Privacy , Department of Justice (DOJ) , Dietary Supplements , Disgorgement , Drug Pricing , Enforcement Actions , False Advertising , False Claims Act (FCA) , Federal Food Drug and Cosmetic Act (FFDCA) , Federal Trade Commission (FTC) , Food and Drug Administration (FDA) , Food Manufacturers , Health Insurance Portability and Accountability Act (HIPAA) , Lanham Act , Life Sciences , Medical Devices , NAD , Off-Label Promotion , OIG , OPDP , Pharmaceutical Industry , Physician Compensation Arrangements , Pleading Standards , POM Wonderful v Coca Cola , REMS , RICO , Risk Assessment , Risk Management , SCOTUS , Tobacco

2/5/2019  /  Amended Rules , Anti-Kickback Statute , Department of Health and Human Services (HHS) , Drug Pricing , Health Care Providers , Health Plan Sponsors , Manufacturers , MCOs , Medicaid , Medicare , Medicare Part D , OIG , Pharmaceutical Industry , Pharmacies , Pharmacy Benefit Manager (PBM) , Prescription Drugs , Proposed Rules , Public Comment , Rebates , Safe Harbors

1/18/2019  /  Affordable Care Act , Constitutional Challenges , Department of Justice (DOJ) , Deregulation , Digital Health , Drug Pricing , Enforcement Actions , False Claims Act (FCA) , Food and Drug Administration (FDA) , Health Care Providers , Health Insurance , Life Sciences , Popular , Tax Credits , Trump Administration , White Collar Crimes

12/13/2018  /  Anti-Bribery , Anti-Corruption , Anti-Kickback Statute , Bribery , Compliance , Corporate Misconduct , Department of Health and Human Services (HHS) , Department of Justice (DOJ) , Digital Health , Drug Pricing , Enforcement Actions , Ethical Standards , False Claims Act (FCA) , FDA Approval , First Amendment , Food and Drug Administration (FDA) , Foreign Corrupt Practices Act (FCPA) , General Data Protection Regulation (GDPR) , Health Care Providers , Health Insurance Portability and Accountability Act (HIPAA) , Internal Investigations , Kickbacks , Life Sciences , Materiality , Medical Devices , OIG , Pharmaceutical Industry , PHRMA , Popular , Product Labels , Rebates , Safe Harbors , Securities and Exchange Commission (SEC) , Sunshine Act , Transparency , Universal Health Services Inc v United States ex rel Escobar , Whistleblowers

3/30/2018  /  Acquisitions , Anti-Kickback Statute , Biotechnology , Charitable Donations , Compliance , Corporate Integrity Agreement , Criminal Prosecution , Department of Justice (DOJ) , Donations , Drug Pricing , Enforcement Actions , False Claims Act (FCA) , First Amendment , Food and Drug Administration (FDA) , Gilead Sciences Inc v United States ex rel Campie , Health Care Providers , Health Insurance Portability and Accountability Act (HIPAA) , HIPAA Breach , Life Sciences , Materiality , Medical Devices , Medicare , Off-Label Promotion , OIG , Park Doctrine , Patient Assistance Programs , Petition for Writ of Certiorari , Pharmaceutical Industry , Popular , Prescription Drugs , Promotional Items , Split of Authority , Universal Health Services Inc v United States ex rel Escobar , Warning Letters , Whistleblowers

2/4/2017  /  Administrative Appointments , Affordable Care Act , Centers for Medicare & Medicaid Services (CMS) , Drug Pricing , Fraud Abuse and Waste , Health Insurance , Health Savings Accounts , Healthcare Fraud , Healthcare Reform , Innovation , Legislative Agendas , Medicaid , Medicare , Pharmaceutical Industry , Prescription Drugs , Repeal , Tax Credits , Trump Administration